SLC5A2 and hydrops fetalis: Likewise, the current American Diabetes Association guidelines recommend using an SGLT2-I with demonstrated CV benefit (empagliflozin, canagliflozin) in T2DM patients with either established atherosclerotic CVD or multiple CV risk factors to reduce the risk of major adverse CV events and/or HF hospitalization.